ENGLEWOOD CLIFFS, NJ, Sept. 30, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the underwriters’ over-allotment option to…


Previous articlePsychedelic Bulletin #119: More Misery for MindMed; Another Psychedelics Co. Ceases Operations; A Brief Dispatch from ICPR
Next articleReunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference